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AbstrAct
Medical care bundles improve standards of 
care and patient outcomes. Acute upper 
gastrointestinal bleeding (AUGIB) is a common 
medical emergency which has been consistently 
associated with suboptimal care. We aimed to 
develop a multisociety care bundle centred on 
the early management of AUGIB.
Commissioned by the British Society of 
Gastroenterology (BSG), a UK multisociety task 
force was assembled to produce an evidence- 
based and consensus- based care bundle detailing 
key interventions to be performed within 
24 hours of presentation with AUGIB. A modified 
Delphi process was conducted with stakeholder 
representation from BSG, Association of Upper 
Gastrointestinal Surgeons, Society for Acute 
Medicine and the National Blood Transfusion 
Service of the UK. A formal literature search was 
conducted and international AUGIB guidelines 
reviewed. Evidence was appraised using the 
Grading of Recommendations, Assessment, 
Development and Evaluation tool and statements 
were formulated and subjected to anonymous 
electronic voting to achieve consensus. Accepted 
statements were eligible for incorporation 
into the final bundle after a separate round 
of voting. The final version of the care bundle 
was reviewed by the BSG Clinical Services and 
Standards Committee and approved by all 
stakeholder groups.
Consensus was reached on 19 statements; these 
culminated in 14 corresponding care bundle 
items, contained within 6 management domains: 
Recognition, Resuscitation, Risk assessment, Rx 
(Treatment), Refer and Review.
A multisociety care bundle for AUGIB has 
been developed to facilitate timely delivery of 
evidence- based interventions and drive quality 
improvement and patient outcomes in AUGIB.
IntroductIon
Acute upper gastrointestinal bleeding 
(AUGIB) is a common medical emer-
gency in the UK with an estimated inci-
dence of 134 per 100 000 population,1 
roughly equating to one presentation 
every 6 min. Mortality following AUGIB 
over the last two decades has remained 
high at approximately 10%,2 with several 
UK- wide audits revealing poor stand-
ards of care.2 3 Multiple guidelines have 
been developed in an attempt to define 
quality standards in AUGIB and improve 
patient outcomes.4–6 These unanimously 
acknowledge the importance of timely 
management within the first 24 hours as 
early resuscitation and endoscopy corre-
late with improved outcomes. Despite 
this, the 2015 UK National Confidential 
Enquiry into Patient Outcome and Death 
(NCEPOD) audit highlighted ongoing 
variations in practice and suboptimal 
care in patients with AUGIB.7 As such, 
strategic initiatives remain necessary to 
address these long- standing deficiencies 
and drive sustained improvement.
The care bundle approach to medical care 
has become increasingly popular in recent 
years.8 Care bundles comprise a pragmatic 
series of evidence- based interventions, 
which when performed together, lead to 
a better outcome than if performed indi-
vidually.8 9 Developed in 2004, the Sepsis 
Six bundle has achieved UK- wide imple-
mentation and has been shown to reduce 
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mortality.10 The 2014 British Society of Gastroenter-
ology (BSG) and British Association for the Study of the 
Liver (BASL) care bundle for decompensated chronic 
liver disease was released in response to NCEPOD 
recommendations,11 and has improved adherence to 
standards of care and reduced length of stay (LOS).12 
In endoscopy, implementation of the Quality Improve-
ment in Colonoscopy bundle led to improvements in 
adenoma detection rates.13 Thus, care bundles can facil-
itate the timely delivery of minimum standards of care, 
which can ultimately improve patient outcomes.8 14 We 
propose that a consensus evidence- based care bundle 
specific for AUGIB and deliverable within the first 
24 hours of presentation could improve the care and 
clinical outcomes of patients with AUGIB. We there-
fore aimed to produce an evidence and consensus- based 
care bundle for the first 24 hours from presentation in 
patients with suspected AUGIB. The bundle is intended 
to be used by all healthcare professionals involved in the 
initial management of patients with AUGIB. Detailed 
endoscopic management is beyond the scope of ward- 
based care and is therefore not included.
Methods
The UK AUGIB care bundle was developed as part of 
the BSG Endoscopy Quality Improvement Programme 
(EQIP).15 The steering committee comprised a multi-
disciplinary group of experts from BSG, Association 
of Upper Gastrointestinal Surgeons, National Health 
Service (NHS) Blood and Transplant, Society for Acute 
Medicine, with trainee and patient representation. 
The consensus process involved a modified Delphi 
method. Members were assigned to working groups 
corresponding to different sections of the care bundle. 
Sequentially, these comprised: Recognition, Resus-
citation, Risk Stratification, Rx (Treatment), Refer 
(referral for endoscopy) and Review (postendoscopic 
management). Each working group framed questions 
relevant to pre- endoscopic and postendoscopic inter-
ventions using the Patient, Intervention, Comparator, 
Outcome (PICO) method, and performed literature 
searches on PUBMED, EMBASE, and Cochrane Data-
base of Systematic Reviews in June 2018. International 
AUGIB guidelines were also reviewed. For guidelines 
produced before 2013, searches were updated using 
original search strategies to identify more recent publi-
cations. Based on the PICO tables, statements relevant 
to early AUGIB management were formulated and 
the level of evidence for each statement appraised in 
accordance with Grading of Recommendations, Assess-
ment, Development and Evaluations methodology.16 
Each statement was paired with a care bundle item. The 
process was peer- reviewed through multiple telecon-
ferences. Once working groups had formulated initial 
evidence- based statements, a face- to- face meeting with 
anonymised electronic voting was arranged to evaluate 
consensus with statements and care bundle items. The 
level of agreement was measured on a five- point Likert 
Scale (A: strongly agree, B: agree, C: neither agree nor 
disagree, D: disagree, E: strongly disagree) following 
evidence appraisal for each statement. The number 
voting for each level was recorded and presented with 
each statement. A threshold of 80% agreement (rated 
A or B) was defined a priori to accept a statement; 
statement revisions were permitted if they did not meet 
this threshold. Each statement underwent up to three 
rounds of voting. Accepted statements were considered 
for incorporation into the final bundle after a sepa-
rate voting process. A level of recommendation (weak/
strong) was assigned to each statement. Although it is 
standard practice to align recommendations with the 
level of evidence, statements could receive discordant 
recommendations (eg, strong recommendation for 
low- quality evidence) if the perceived benefit in clinical 
practice outweighed the paucity of available evidence. 
The final version of the care bundle was reviewed and 
approved by stakeholder groups, including the BSG 
Clinical Services and Standards Committee, prior to 
submission for publication. Focused top- up searches 
were also performed in October 2019 to ensure that 
the evidence was updated prior to publication.
consensus stAteMents
Following evidence review, the modified Delphi 
process reached consensus on 19 recommendations 
(table 1). These culminated into 14 corresponding care 
bundle items (figure 1), enveloped within six manage-
ment domains: Recognition, Resuscitation, Risk strat-
ification, Rx (Treatment), Referral and Review (post- 
endoscopy care).
recognItIon
We recommend that patients with haematemesis, 
melaena or coffee ground vomiting (cgV) in the absence 
of an alternate diagnosis (eg, bowel obstruction) trigger 
the AugIb bundle
Level of evidence: Low
Level of recommendation: Strong
Agreement: 100%
Bundle recommendation: Trigger bundle if haematem-
esis, melaena or CGV (100% agreement)
Haematemesis and melaena are recognised symp-
toms of AUGIB. CGV refers to emesis that contains 
dark altered blood not due to any other cause such 
as bowel obstruction or sepsis. The appropriateness 
of including CGV as a trigger for the AUGIB bundle 
was evaluated. A recent study (n=3012) prospectively 
compared outcomes following presentation with CGV 
compared with overt haematemesis and/or melaena.17 
Clinical severity measured using risk stratification tools 
were all significantly lower in the isolated haematem-
esis group than in the CGV group, as CGV was asso-
ciated with older patients with comorbidity. Although 
haematemesis was independently associated with 
higher rates of haemostatic intervention and rebleeding 
than CGV, there were no significant differences in the 
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Table 1 Summary of recommendation statements
Recommendation statement
level of 
evidence
level of 
recommendation
We recommend that patients with haematemesis, melaena, or coffee ground vomiting in the absence of an 
alternate diagnosis (eg, bowel obstruction) trigger the acute upper gastrointestinal bleeding (AUGIB) bundle.
Low Strong
We recommend that patients with suspected AUGIB should have urgent observations performed using a 
validated early warning score such as the National Early Warning Score (NEWS).
Low Strong
We recommend all patients with AUGIB be commenced on intravenous fluids. We recommend in 
haemodynamically unstable patients a crystalloid solution as a bolus of 500 mL in less than 15 min.
Very low Strong
We recommend that red blood cell transfusion should follow a restrictive protocol (trigger: Hb <70 g/L; target: 
70–100 g/L). A higher trigger should be considered in patients with ischaemic heart disease or haemodynamic 
instability.
High Strong
We recommend that patients with AUGIB with ongoing haemodynamic instability are referred for critical care 
review.
Very low Strong
We suggest that platelets should be given in active acute upper GI bleeding with a platelet count ≤50×109/L, as 
per major haemorrhage protocols.
Very low Weak
We recommend the Glasgow- Blatchford Score (GBS) is calculated at presentation with AUGIB. Moderate Strong
We recommend that patients with GBS ≤1 at presentation are considered for outpatient management. Moderate Strong
We recommend intravenous terlipressin is given to all patients with suspected cirrhosis/variceal bleeding. 
However, caution should be exercised in patients with ischaemic heart disease or peripheral vascular disease.
High Strong
We recommend giving intravenous antibiotics as per local protocol to patients with suspected cirrhosis/variceal 
bleeding.
High Strong
We recommend continuing aspirin at presentation. Moderate Strong
We recommend interrupting P2Y12 inhibitors until haemostasis is achieved unless the patient has coronary 
artery stents, in which case, a decision should be undertaken after discussion with a cardiologist.
Moderate Strong
We recommend interrupting warfarin therapy at presentation. Low Strong
We recommend interrupting direct oral anticoagulant therapy at presentation. Low Strong
We recommend endoscopy is offered to patients admitted with suspected AUGIB within 24 hours of 
presentation. Patients with ongoing haemodynamic instability will require more urgent endoscopy after 
resuscitation.
Low Strong
We suggest that the endoscopy report should be reviewed by the ward team. Very low Strong
We suggest that all patients with varices or those requiring endoscopic therapy are referred to a specialist 
gastroenterology service.
Low Strong
We recommend patients with bleeding from ulcers with high- risk stigmata at endoscopy receive high- dose 
intravenous proton pump inhibitor (PPI) therapy; high- dose oral PPIs may be considered as an alternative.
High Strong
We recommend patients with AUGIB in whom antithrombotic therapy is interrupted have a clear plan for 
resumption.
Low Strong
composite outcome of transfusion requirement, endo-
scopic intervention or death between presenting symp-
toms. Hence CGV should be considered a presenting 
feature of AUGIB.
resuscItAtIon
We recommend that, on admission or presentation with 
suspected AugIb, urgent observations be performed 
using a validated early warning score such as the 
national early Warning score (neWs)
Level of evidence: Low
Level of recommendation: Strong
Agreement: 80%
Bundle recommendation: Perform NEWS (100% 
agreement)
All patients with AUGIB require urgent assessment 
of their haemodynamic status followed by reassess-
ment at regular intervals. Early warning scores serve 
as a composite indicator of a patient’s physiological 
status and are used to identify deteriorating patients 
and trigger medical interventions. These can be used 
to determine bleeding severity, screen for rebleeding 
in stable patients, guide fluid resuscitation and deter-
mine intervention, for example, frequency of obser-
vations, escalation of care, and so on. The role of 
early warning scores in AUGIB has been presented 
in a single- centre study (n=202) which compared a 
Modified Early Warning Score (MEWS) based on five 
admission parameters (systolic blood pressure, heart 
rate, respiratory rate, temperature and consciousness 
level) with the Glasgow- Blatchford Score (GBS) and 
the Pre- endoscopic Rockall (PER) Score in predicting 
outcomes.18 There was significant correlation between 
the admission MEWS and the outcomes of hospital 
admission and death (p<0.001). MEWS >2 was supe-
rior for predicting mortality (area under the receiver 
operating characteristics curve (AUROC) 0.772, 
p<0.001) compared with GBS >13 (AUROC 0.679, 
p=0.022) and PER Score (AUROC 0.767, p<0.001). 
 o
n
 April 6, 2020 by guest. Protected by copyright.
http://fg.bmj.com/
Frontline G
astroenterol: first published as 10.1136/flgastro-2019-101395 on 27 M
arch 2020. Downloaded from
 
Siau K, et al. Frontline Gastroenterology 2020;0:1–13. doi:10.1136/flgastro-2019-1013954
 
Figure 1 Summary of the BSG- led acute upper gastrointestinal bleeding care bundle. NEWS, National Early Warning Score; PPI, proton pump 
inhibitor
MEWS >1 was also predictive of transfusion require-
ments (AUROC 0.584, p=0.047), but not rebleeding 
(AUROC 0.617, p=0.064) or endoscopic therapy 
(AUROC 0.508, p=0.862).18
NEWS has received endorsement by the Royal College 
of Physicians and NHS England for use in all acutely ill 
patients.19 To align with these recommendations, we 
recommend the use of NEWS, or a similarly validated 
early warning score, at presentation with suspected 
AUGIB.
We recommend all patients with AugIb be commenced 
on intravenous fluids. We recommend a crystalloid 
solution with a bolus of 500 mL over less than 15 min, in 
haemodynamically unstable patients
Level of evidence: Very low
Level of recommendation: Strong
Agreement: 100%
Bundle recommendation: Commence intravenous 
crystalloid (80% agreement)
Haemodynamic instability is defined by the National 
Institute for Health and Care Excellence (NICE) as 
active bleeding where blood pressure or pulse cannot 
be normalised or where rapid intravenous fluids are 
required to maintain haemodynamic stability.5 There 
are no randomised controlled trials (RCTs) comparing 
different fluid regimens in AUGIB.
Two small non- randomised studies assessed the volume 
of fluid administration in AUGIB. The first (n=51) 
included patients with variceal bleeding and haemor-
rhagic shock and compared dopamine with restricted 
fluid versus liberal fluids only.20 There were no significant 
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differences in mortality or LOS, but evidence of reduc-
tions in acute respiratory distress syndrome, multiorgan 
failure and sepsis in favour of the dopamine group. The 
second associated early intensive resuscitation in AUGIB 
with reduced rates of mortality and myocardial infarc-
tion.21 However, the intervention involved a physician 
providing dedicated one- to- one input (no other clinical 
duties other than caring for the patient with AUGIB) and 
therefore cannot be proposed as standard care in routine 
clinical practice.
The NICE guideline on intravenous fluids recom-
mends fluid resuscitation with 500 mL crystalloid over 
less than 15 min.22 This is based on a Cochrane review 
comparing crystalloids with colloids in critically ill 
patients.23 The European Society of Gastrointestinal 
Endoscopy (ESGE) AUGIB guidelines6 contain a recom-
mendation on prescribing intravenous fluids based on 
this Cochrane review23 and a high- quality single- centre 
RCT.24 ESGE guidelines recommend prompt intra-
vascular volume replacement using crystalloid fluids if 
haemodynamic instability exists.6 Fluid administration 
has not featured in other AUGIB guidelines.
Regardless of haemodynamic status at presentation, 
we recommend that all patients with AUGIB should be 
commenced on intravenous fluid replacement and that 
monitoring of NEWS and clinical review are required 
to determine the infusion rate.
We recommend that red blood cell (rbc) transfusion 
should follow a restrictive protocol (trigger: hb 
<70 g/L; target: 70–100 g/L). A higher trigger should be 
considered in patients with ischaemic heart disease or 
haemodynamic instability
Level of evidence: High
Level of recommendation: Strong
Agreement: 100%
Bundle recommendation: Transfuse if Hb <70 g/L 
with a target of 70–100 g/L (100% agreement)
Five RCTs have assessed the use of different trans-
fusion thresholds;25–29 these were summarised in a 
systematic review (n=1965).30 Ninety- three per cent of 
patients were derived from two RCTs which included 
both variceal and non- variceal AUGIB.26 27 Only one 
RCT included participants regardless of age, comor-
bidity or history of ischaemic heart disease.26 The study 
by Villanueva et al (n=889) was a single- centre Spanish 
RCT that compared a threshold of 70 g/L with 90 g/L.27 
All participants received endoscopy within 6 hours. 
The study by Jairath et al was a multicentre UK cluster 
randomised RCT that compared a threshold of 80 g/L 
with 100 g/L.26 In the meta- analysis, a restrictive transfu-
sion strategy was associated with a reduction in all- cause 
mortality at 30 days (26 fewer deaths per 1000; 95% 
CI 2 to 42); rebleeding (57 fewer rebleeding episodes 
per 1000; 95% CI 21 to 81), transfusion requirement 
(mean difference −1.73 RBC units; 95% CI −2.36 to 
−1.11); number of people who required a transfusion 
(276 fewer per 1000; 95% CI 164 to 361) and LOS 
(mean difference −1.9 days; 95% CI 3.34 to 0.46).30 
No difference was found between the variceal and non- 
variceal subgroups. No RCTs included participants with 
exsanguinating haemorrhage, where haemoglobin may 
not be an accurate measure of blood loss.31 In such cases, 
patients should be managed in line with major haem-
orrhage guidelines.32 Rates of RBC transfusion should 
be guided by the speed of blood loss and the level of 
haemodynamic compromise.32
We recommend that patients with AugIb with ongoing 
haemodynamic instability are referred for critical care 
review
Level of evidence: Very low
Level of recommendation: Strong
Agreement: 100%
Bundle recommendation: If haemodynamically 
unstable, consider activating major haemorrhage 
protocol and arranging critical care review (added as 
standalone statement in bundle)
The study by Baradarian et al associated inten-
sive monitoring and management of haemodynamic 
instability with improved outcomes.21 Patients with 
AUGIB may also suffer complications caused by non- 
hypovolaemic causes of shock, for example, sepsis 
in patients with cirrhosis. Haemodynamic instability 
per se should not be the sole determinant for critical 
care admission.33 In cases of ongoing haemodynamic 
instability despite adequate resuscitative efforts, acti-
vation of the major haemorrhage protocol should be 
considered in addition to early referral to a critical 
care specialist in order to optimise circulatory manage-
ment.32 34
We suggest that platelets should be given in active 
AugIb with a platelet count ≤50 × 109/L, as per major 
haemorrhage protocols
Level of evidence: Very low
Level of recommendation: Weak
Agreement: 90%
Bundle recommendation: Keep platelet count >50 
(included as part of major haemorrhage protocol, there-
fore no separate statement required)
No RCTs have assessed the role of platelet trans-
fusions or platelet transfusion thresholds.35 There is 
little evidence for the effectiveness of platelet trans-
fusions or the optimal dose when a patient with a 
thrombocytopenia is actively bleeding.36 In patients 
without pre- existing thrombocytopenia, acquired 
thrombocytopenia may be a late event in major haem-
orrhage, occurring after blood loss of at least 1.5 total 
blood volumes.32 Guidance for a platelet transfusion 
threshold in major bleeding is based on expert opinion 
only, and is consistently recommended by NICE5 37 
and the British Society for Haematology.32 Due to the 
limited evidence and its coverage within the major 
haemorrhage protocol, a separate bundle statement 
for thrombocytopaenia correction was not included.
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rIsk strAtIfIcAtIon
We recommend gbs is calculated at presentation with 
AugIb
Level of evidence: Moderate
Level of recommendation: Strong
Agreement: 100%
Bundle recommendation: Calculate GBS (100% agree-
ment)
We recommend that patients with gbs ≤1 at presentation 
are considered for outpatient management
Level of evidence: Moderate
Level of recommendation: Strong
Agreement: 100% Agreement
Bundle recommendation: Consider discharge if GBS 0 
or 1 (100% agreement)
Several comparative studies have assessed pre- 
endoscopy and postendoscopy risk scores in 
AUGIB.38–49 These studies confirm GBS is the best 
at predicting the clinically important composite end 
point of need for hospital- based intervention (trans-
fusion, endoscopic therapy, interventional radiology, 
surgery) or death, with high sensitivity at 98.6%.39 
The clinical utility of existing risk scores to iden-
tify patients at high risk of poor outcomes appear 
limited. The AIMS65 and PER Scores appear best at 
predicting death after AUGIB,41 42 44 46 50 and use of 
the full Rockall Score following endoscopy has previ-
ously been recommended to predict mortality.5 51 52 
However the AUROC figures for mortality using these 
scores are relatively low.39 The accuracy of risk scores 
to identify need for endoscopic therapy or rebleeding 
is also relatively low.38 39 43 48 53 54
A systematic review of pre- endoscopy risk scores 
found that GBS was the optimal pre- endoscopy risk 
score with GBS of zero demonstrating high sensitivity 
but low specificity for predicting adverse outcomes.40 
Although GBS of zero has historically been used to 
identify very low- risk patients suitable for outpatient 
management,5 48 55 56 recent large multicentre studies 
have suggested this threshold could be increased to 
GBS ≤1.38 39 49 57 This GBS threshold strategy has 
been recommended by recent international AUGIB 
guidelines.4 6 The recently described pre- endoscopic 
CANUKA Score shows promise in identifying low- 
risk patients presenting with UGIB, however only 7% 
patients were encompassed by its low- risk threshold, 
compared with 24% using the GBS ≤1 threshold.58 
Further data on this score are awaited.
rX (treAtMent)
We recommend intravenous terlipressin is given to all 
patients with suspected cirrhosis/variceal bleeding. 
however, caution should be exercised in patients with 
ischaemic heart disease or peripheral vascular disease
Level of evidence: High
Level of recommendation: Strong
Agreement: 100%
Bundle recommendation: Intravenous terlipressin 2 mg 
four times a day in case of suspected variceal bleeding 
(80% agreement)
Variceal bleeding should be suspected in patients 
presenting with AUGIB who have known cirrhosis or 
have clinical parameters that would suggest cirrhosis. 
The UK variceal bleed guidelines recommend admin-
istering terlipressin or somatostatin as soon as vari-
ceal bleeding is suspected,59 for up to 5 days or until 
attainment of haemostasis, with octreotide as an 
alternative. The efficacy of intravenous terlipressin in 
variceal bleeding has been presented in a Cochrane 
meta- analysis of 22 RCTs (n=1609).60 Seven studies 
(n=443) compared terlipressin to placebo, of which 
five were considered to be high quality. This showed 
a significant reduction in all- cause mortality compared 
with placebo (34% relative risk reduction), improved 
haemostasis and reduced transfusion requirement. 
Similar results were found in an updated meta- analysis 
in 2012.61 A more recent multicentre RCT (n=780) 
reported non- inferiority of terlipressin compared 
with octreotide and somatostatin, with no difference 
in outcomes of haemorrhage control, rebleeding and 
mortality.62 The BSG/BASL cirrhosis bundle suggests 
caution in patients with known ischaemic heart disease 
or peripheral vascular disease and mandatory ECG 
assessment in patients aged over 65 years.11
We recommend giving intravenous antibiotics to all 
patients with suspected cirrhosis/variceal bleeding
Level of evidence: High
Strength of recommendation: Strong
Agreement: 100%
Bundle recommendation: Intravenous antibiotics if 
suspected cirrhosis/variceal bleeding (100% agree-
ment)
Bacterial infections are common in patients with 
cirrhosis and AUGIB and are associated with rebleeding 
and mortality.63 A Cochrane meta- analysis of 12 RCTs 
(n=1241) concluded that antibiotic prophylaxis in 
this context was superior to placebo in reducing 
mortality, bacterial infections, rebleeding and LOS.64 
The benefit of antibiotic prophylaxis has also been 
observed following endoscopic haemostasis for peptic 
ulcer bleeding.65 66 There is evidence to support the 
use of intravenous prophylactic antibiotics over oral 
agents. Fernandez et al67 randomised patients (n=111) 
with AUGIB and cirrhosis to either oral norfloxacin 
(400 mg twice daily) or intravenous ceftriaxone (1 g/
day) for 7 days, and assessed outcomes within 10 days. 
Patients assigned to intravenous ceftriaxone had lower 
rates of proven infections, bacteraemia and sponta-
neous bacterial peritonitis. In accordance with the 
BSG/BASL cirrhosis bundle, patients with cirrhosis 
and AUGIB should be empirically managed as variceal 
bleeding and commenced on antibiotic prophylaxis 
according to local antimicrobial policy.
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We recommend continuing aspirin at presentation
Level of evidence: Moderate
Level of recommendation: Strong
Agreement: 90%
Bundle recommendation: Continue aspirin (80% 
agreement)
We recommend interrupting P2Y12 inhibitors until haemostasis is 
achieved unless the patient has coronary artery stents, in which case, a 
decision should be undertaken after discussion with a cardiologist
Level of evidence: Moderate
Level of recommendation: Strong
Agreement (Round 3): 80%
Bundle recommendation: Unless the patient has major 
AUGIB, continue P2Y12 inhibitor in patients with 
coronary artery stents until discussion with cardiology 
(60% agreement—rejected)
We recommend interrupting warfarin therapy at presentation
Level of evidence: Low
Level of recommendation: Strong
Agreement: 80%
Bundle recommendation: Suspend warfarin (100% 
agreement)
We recommend interrupting direct oral anticoagulant (DOAC) therapy 
at presentation
Level of evidence: Low
Level of recommendation: Strong
Agreement: 90%
Bundle recommendation: Suspend DOAC (100% 
agreement)
AntIthroMbotIc therApy
Antithrombotic therapy confers a balance of beneficial 
antithrombotic effects versus risk of AUGIB. In AUGIB, 
emergency endoscopy can provide effective haemo-
stasis, and antithrombotic therapy may be temporarily 
interrupted depending on the indication.68
AspIrIn
In patients on low- dose aspirin for secondary preven-
tion, aspirin discontinuation is associated with a three-
fold increased risk of cardiovascular or cerebrovas-
cular events, the majority of which occurred within 
7–10 days.69 70 An RCT comparing continuation of 
low- dose (80 mg) aspirin therapy or discontinuation 
(placebo) following endoscopic haemostasis for peptic 
ulcer bleeding found increased incidence of recurrent 
bleeding in the continuation group (10.3% vs 5%) 
but lower all- cause mortality (1.3% vs 12.9%).71 All 
patients received intravenous proton pump inhib-
itor (PPI) therapy. It should be noted that aspirin was 
discontinued for 8 weeks in the placebo group.
p2y12 receptor antagonists
P2Y12 receptor antagonists, for example, clopidogrel, 
prasugrel and ticagrelor, are commonly co- prescribed 
with aspirin as DAPT. DAPT is generally recommended 
for 12 months after deployment of drug- eluting coro-
nary artery stents or 1 month for bare metal stents. 
There is a high risk of stent thrombosis, with up to 
a 40% risk of acute myocardial infarction or death if 
DAPT therapy is discontinued within this period.72 
Ideally, DAPT for coronary stents should be continued 
due to the consequences of stent thrombosis, and it 
is important to liaise with a cardiologist in the emer-
gency setting. In the event of severe haemorrhage, 
it may be necessary to temporarily discontinue the 
P2Y12 inhibitor, but aspirin should be continued,73 
with the aim to restart the P2Y12 inhibitor within 5 
days .74 This recommendation is consistent with inter-
national guidelines,68 75 but due to the lack of AUGIB- 
specific studies and the complexity of the statement, 
the steering group did not recommend this statement 
as a stand- alone item in the care bundle.
WArfArIn
Indications for warfarin can be characterised into low 
risk or high risk for thrombosis.68 Warfarin can be 
interrupted on presentation with AUGIB, but a plan 
for resumption should be made. Specific advice on the 
management of patients in whom reversal of anticoag-
ulation is indicated are outside the scope of this bundle 
but are available in published guidelines.68
dIrect orAL AntIcoAguLAnts
Dabigatran is a thrombin inhibitor, whereas rivarox-
aban, apixaban and edoxaban are factor Xa inhibi-
tors. Unlike warfarin, DOACs have relatively short 
half- lives, which may be prolonged in renal failure. 
For minor AUGIB, it is usually sufficient to withhold 
DOAC therapy and allow the effect to dissipate; severe 
AUGIB is challenging and advice should be sought 
from a haematologist. In the case of life- threatening 
haemorrhage, idarucizumab has been developed as an 
antidote for dabigatran,76 and andexanet for the anti-
factor Xa inhibitors.77
refer
We recommend endoscopy is offered to patients 
admitted with suspected AugIb within 24 hours of 
presentation. patients with ongoing haemodynamic 
instability will require more urgent endoscopy after 
resuscitation
Level of evidence: Weak
Level of recommendation: Strong
Agreement: 90%
Bundle recommendation: Referral to ensure that 
endoscopy is performed within 24 hours of presenta-
tion (100% agreement)
Endoscopy is the primary diagnostic and therapeutic 
modality in AUGIB. Time to endoscopy, that is, time 
from admission/inpatient presentation to endoscopy, is 
a recognised quality metric in AUGIB.
Two systematic reviews which studied the effect 
of early endoscopy (≤24 hours) found no benefit 
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on mortality and the need for surgery but identi-
fied a reduction in LOS.78 79 Several studies assessed 
the effect of endoscopy timing on clinical outcome 
in non- variceal AUGIB, although these differed in 
study design. One US study identified delayed endos-
copy (>24 hours after admission) as an independent 
predictor of mortality in both variceal bleeding and 
non- variceal AUGIB.80 The role of very early endos-
copy (<12 hours) in patients with NVUGIB remains 
controversial.81 82 Endoscopy within 12 hours (vs 
12–24 hours) has been associated with lower trans-
fusion requirements.81 One retrospective analysis 
assessed timing of endoscopy in low- risk (GBS ≤12) 
versus high- risk (GBS ≥12) patients.82 The timing of 
endoscopy did not impact on inpatient mortality in 
low- risk patients, but was significant in the high- risk 
group, where a threshold of 13 hours was optimal for 
predicting survival.82 No differences were reported 
for transfusion requirements, rebleeding or need for 
surgery, which suggests that mortality in these patients 
may be unrelated to AUGIB.82 An RCT from Hong 
Kong compared <6 hours vs <24 hours endoscopy 
in high- risk patients (GBS ≥12),83 with preliminary 
results reporting no difference in major outcomes.
In contrast, a retrospective study (n=81) found no 
differences in clinical outcomes (mortality, rebleeding 
or surgery or LOS) between patients receiving endos-
copy within 3 hours vs 48 hours. There was however a 
higher need for endoscopic therapy in the early endos-
copy group (p=0.002).84
Several studies have associated very early endoscopy 
(<12 hours) with adverse outcomes. A retrospective 
study (n=361) reported that patients undergoing endos-
copy within 12 hours for AUGIB had a fivefold increased 
risk of incurring the composite outcome of rebleeding, 
surgical or radiological intervention or need for repeat 
endoscopic intervention.85 Other confounders may 
exist, but one possible explanation could be inadequate 
resuscitation, as patients who underwent early endos-
copy had significantly lower blood pressure and higher 
heart rate. A nationwide cohort study of patients with 
peptic ulcer bleeding from Denmark (n=12 601) asso-
ciated endoscopy undertaken too early, or too late, with 
higher mortality, particularly in patients with higher 
levels of comorbidity or haemodynamic instability.86 The 
authors suggested that a period of 6–12 hours prior to 
endoscopy may allow time for resuscitation and medical 
optimisation.
Most guidelines recommend endoscopy for all 
patients within 24 hours, and for patients with haemo-
dynamic instability to undergo more urgent endos-
copy.5 6 87 ESGE guidelines also recommend very 
early endoscopy in those with contraindications to 
the interruption of anticoagulation, although data 
were limited.6 For suspected acute variceal bleeding, 
the European and American guidelines suggest endos-
copy with 12 hours.88 89 However, the 2015 UK vari-
ceal bleeding guidance proposes endoscopy within 
24 hours for all, except for unstable patients who 
should have endoscopy immediately after resuscita-
tion,59 as changing the timing of endoscopy to within 
12 hours has not been shown to be associated with a 
survival benefit.90
Based on the available evidence and international 
guidelines, we recommend that all patients with 
AUGIB undergo endoscopy within 24 hours of admis-
sion, with earlier endoscopy for those with ongoing 
haemodynamic instability. The endoscopy referral or 
request should be made in a timely manner in order to 
achieve this outcome.91
reVIeW
We suggest that the endoscopy report should be 
reviewed by the ward team
Level of evidence: Very low
Level of recommendation: Strong
Agreement: 90%
Bundle recommendation: Review endoscopy report 
(100% agreement)
The endoscopy report provides an overview of each 
procedure. For AUGIB, this should include endoscopic 
findings and haemorrhagic stigmata, therapies adminis-
tered, certainty of haemostasis, complications, further 
management and rebleeding plan.7 92 One Canadian 
prospective study studied the impact of a checklist on 
the endoscopy report in patients with non- variceal 
AUGIB,93 which included instructions on diet, drugs 
and discharge. Checklist compliance led to reductions 
in LOS. Although the impact of a rebleeding plan 
has not been specifically studied, this featured in the 
NCEPOD recommendations as a pragmatic and clini-
cally relevant standard of care.7 On their return to the 
ward following endoscopy, the patient and endoscopy 
report should be reviewed by the receiving ward team 
and management recommendations instigated.
We suggest that all patients with varices or those 
requiring endoscopic therapy are referred to a 
gastroenterology service
Level of evidence: Low
Level of recommendation: Strong
Agreement: 90%
Bundle recommendation: Refer to GI specialist if 
requiring therapeutic endoscopy (100% agreement)
Several studies have assessed the role of specialist 
care for AUGIB under gastroenterology teams. A single- 
centre prospective UK study by Sanders et al assessed 
the outcomes of 900 consecutive patients with AUGIB 
admitted to a dedicated GI bleeding unit.94 All patients 
received protocolised care by dedicated gastroenterolo-
gists and nurses, and had access to 24 hours endoscopy 
and interventional radiology. Compared with data from 
the 1995 UK audit of AUGIB, mortality adjusted by 
PER and post- endoscopy Rockall Scores were signifi-
cantly lower in the specialist unit. This study echoed 
the findings of a previous retrospective UK- based study 
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without propensity matching.95 A retrospective Italian 
multicentre analysis (n=13 427) reported that specialist 
gastroenterology care was associated with reduced 
30- day mortality (OR 0.55, 95% CI 0.37 to 0.82), which 
remained significant after propensity adjustment and in 
patients receiving endoscopy.96
Based on the study by Sanders et al, the Scottish 
Intercollegiate Guidelines Network recommended 
that patients with AUGIB should be admitted, assessed 
and managed in a dedicated gastrointestinal bleeding 
unit.87 We recommend that patients with endoscopi-
cally confirmed AUGIB, particularly those requiring 
therapeutic haemostasis, should be referred to a 
specialist service for ongoing input. Patients with 
evidence of varices are at risk of decompensation from 
underlying cirrhosis, and should also be referred for 
specialist care and follow- up.
We recommend patients with bleeding from ulcers 
with high-risk stigmata at endoscopy receive high dose 
intravenous proton pump inhibitor (ppI) therapy; high-
dose oral ppIs may be considered as an alternative
Level of evidence: High
Level of recommendation: Strong
Agreement: 90%
Bundle recommendation: PPI if high risk ulcer post- 
endoscopy (100% agreement)
The role of PPI infusion in patients with high- risk, 
non- variceal AUGIB is supported by meta- analysis 
data.97 98 The NICE guidelines recommend offering 
PPI to patients with non- variceal AUGIB with endo-
scopic stigmata of recent haemorrhage,5 whereas ESGE 
recommends intravenous PPI for patients requiring 
endoscopic haemostasis or ulcers with adherent clot.6 
Although PPI infusion (80 mg bolus followed by 8 mg/
hour for 72 hours) was recommended, intermittent 
intravenous PPI and oral high- dose PPI could be 
considered as alternatives.4 6
A meta- analysis of 13 RCTs comparing various regi-
mens of intermittent intravenous PPI with PPI infusion 
following endotherapy for high- risk bleeding peptic 
ulcers reported non- inferiority with intermittent PPI 
therapy for the outcomes of rebleeding, mortality, 
urgent interventions, LOS or transfusion require-
ments.99 The authors concluded that intermittent 
bolus regimens could be used as an alternative to infu-
sion therapy.
RCT and meta- analysis data have failed to demonstrate 
superiority of PPI therapy based on dosage or route of 
PPI administration as an adjunct to endoscopic therapy 
for peptic ulcer disease.100–102 The Asia- Pacific guide-
lines suggest that, as an adjunct to endoscopic treatment, 
high- dose oral PPI can be used to prevent rebleeding.4
We recommend patients with AugIb in whom 
antithrombotic therapy is interrupted have a clear plan 
for resumption
Level of evidence: Low
Level of recommendation: Strong
Agreement: 100%
Bundle recommendation: Posthaemostasis antithrom-
botic plan (100% agreement)
Antithrombotic therapy is often stopped following 
AUGIB and a clear plan for resumption not made 
on discharge. Antithrombotic resumption is associ-
ated with improved survival and reduced incidence 
of thrombotic complications.103 Thus, all patients in 
whom antithrombotic therapy has been interrupted 
should have a clear plan for resumption.
Detailed discussion on the timing of antithrombotic 
resumption is beyond the scope of this bundle but is 
available from international guidelines.4 6 68 75 Inclu-
sion of a statement on resumption of antithrombotics 
was unanimously supported by the working group.
dIscussIon
Despite the availability of multiple high- quality 
international guidelines, recent evidence confirms 
persisting poor performance in managing patients 
with AUGIB.7 91 The BSG EQIP has identified a clinical 
need to improve the quality of endoscopy and service 
provision in AUGIB. Previous interventions in the UK, 
for example in colonoscopy training and certification, 
provided by the Joint Advisory Group on Gastroin-
testinal Endoscopy, have been shown to significantly 
improve performance and outcomes in clinical prac-
tice.104 In addition, other care bundles such as the 
BSG/BASL cirrhosis bundle have led to improvements 
in patient- centred outcomes.12
Many of the areas for possible improvement in 
AUGIB management are in the pre- endoscopy and 
post- endoscopy care of patients either admitted with 
AUGIB to hospital or who develop bleeding while 
hospitalised with another condition. We have there-
fore convened a multidisciplinary, multisociety devel-
opment group to construct a care bundle targeted at 
non- specialist staff in emergency departments, acute 
medical or surgical wards aiming to improve manage-
ment in the first 24 hours of care.
In developing this bundle, we have focused on 
six domains with 14 bundle items. The care bundle 
comprises a series of evidence- based measures which 
are associated with improved outcomes compared with 
if they were not performed. In addition, preliminary 
evidence has reported improved outcomes when using 
the bundle.105 The brevity and choice of items make this 
a simple and quick tool to enhance utilisation in busy 
clinical practice. We believe that, if implemented, the 
AUGIB bundle could ensure standardised, evidence- 
based care of the highest quality in hospitals in the UK 
and in other international healthcare environments.
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